A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : TNFis / tumor necrosis factor inhibitors

[Related PubMed/MEDLINE]
Total Number of Papers: 48
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   TNFis  (>> Co-occurring Abbreviation)
Long Form:   tumor necrosis factor inhibitors
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 A Budget Impact and Cost Per Additional Responder Analysis for Baricitinib for the Treatment of Moderate-to-Severe Rheumatoid Arthritis in Patients with an Inadequate Response to Tumor Necrosis Factor Inhibitors in the USA. ACR, BIM, csDMARD, DMARDs, JAK, NMA, NNT, RA
2020 Anti-citrullinated protein antibody titre as a predictor of abatacept treatment persistence in patients with rheumatoid arthritis: a prospective cohort study in Japan. ACPA, RA
2020 Biologic Agents Reduce Cardiovascular Events in Rheumatoid Arthritis Not Responsive to Tumour Necrosis Factor Inhibitors: A National Cohort Study. CI, CV, HR, MACE, RA
2020 Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort. axSpA, PS, SEC
2020 Insensitivity versus poor response to tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective cohort study. bDMARD, DAS28-CRP, RA
2020 Persistence on biologic DMARD monotherapy after achieving rheumatoid arthritis disease control on combination therapy: retrospective analysis of corrona registry data. bDMARDs, csDMARDs, LDA
2020 Psoriatic arthritis treatment patterns and costs among pharmacologic treatment-naive patients. OSMs, PDE4, PsA
2020 Risk of neuroinflammatory events in arthritis patients treated with tumour necrosis factor alpha inhibitors: a collaborative population-based cohort study from Denmark and Sweden. ---
2020 Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Slovenia: a cohort study. AS, IRs, LTBI, PsA, PY, RA, SIRs, TB
10  2020 Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence. mSASSS
11  2020 What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis? ADAs, BP, RA, TDM
12  2019 An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States. ADA, GOL, IFX, PMPM, TOFA, UC, VEDO
13  2019 Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis. DMARDs, JAK, RA
14  2019 Comparative effect of tumour necrosis factor inhibitors versus other biological agents on cardiovascular risk-associated biomarkers in patients with rheumatoid arthritis. CVD, LAR, RA, ROC, TCZ
15  2019 Comparative Effectiveness of Abatacept Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis Who Are Anti-CCP Positive in the United States Corrona Registry. ACPAs, bDMARDs, CDAI, RA
16  2019 Comparison of the Safety and Efficacy of Tumor Necrosis Factor Inhibitors and Interleukin-17 Inhibitors in Patients With Psoriasis IL, PsO
17  2019 Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis. csDMARDs, ICER, MTX, RA
18  2019 Discontinuation and switching patterns of tumour necrosis factor inhibitors (TNFis) in TNFi-naive and TNFi-experienced patients with psoriatic arthritis: an observational study from the US-based Corrona registry. PsA, TNFi
19  2019 Effect of Biological Disease-modifying Anti-rheumatic Drugs on Airway and Interstitial Lung Disease in Patients with Rheumatoid Arthritis. ABT, AD, bDMARDs, CT, ILD, RA, TCZ
20  2019 Effectiveness of Subcutaneous Tumor Necrosis Factor Inhibitors in Patients With Ankylosing Spondylitis: A Real-World Prospective Observational Cohort Study in China. AS, BASFI, BASMI, CASPIC
21  2019 Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naive Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis. ACR, CI, HAQ, RA, RCTs
22  2019 Risk of Serious Infection in Patients With Rheumatoid Arthritis Treated With Biologic Versus Nonbiologic Disease-Modifying Antirheumatic Drugs. bDMARDs, CI, csDMARDs, DMARDs, HR, PS, RA, SIs
23  2019 The persistence of golimumab compared to other tumour necrosis factor-alpha inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si. AS, PsA, RA
24  2019 Use of FDA-Approved Medications: Biologics for Psoriatic Arthritis in Patients at an Urban Outpatient Rheumatology Clinic. ACR, FDA, IL-17, IL-23, OSMs, PsA
25  2019 Use of tumor necrosis factor-alpha inhibitors during pregnancy among women who delivered live born infants. AS, CD, JIA, PsA, PsO, RA, UC
26  2018 Evaluation of the comorbidity burden in patients with ankylosing spondylitis treated with tumour necrosis factor inhibitors using a large administrative claims data set. AS, HR
27  2018 Sarilumab for Previously-Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. bDMARDs, cDMARDs, ERG, HAQ-DI, ICERs, MTX, NHS, NICE, NMAs, QALY, RA, RTX, SAR, STA
28  2018 The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future. AAU, bDMARDs, SpA
29  2018 The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus phototherapy: An observational cohort study. ---
30  2018 TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. AS, ASDAS, mSASSS
31  2018 Tumor Necrosis Factor Inhibitor Discontinuation in Patients with Ankylosing Spondylitis: An Observational Study From the US-Based Corrona Registry. AS
32  2017 Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry. PsA
33  2017 Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). bDMARDs, FACIT-F, HAQ-DI, MJS, PROs, PtGA, RA-BEACON
34  2017 Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis. ACR, EULAR, IMRDs, ISPOR, OLE, RCTs, s.c
35  2016 Combination therapy with biologic agents in rheumatic diseases: current and future prospects. bDMARDs, csDMARDs, DMARDs, GCs, MTX, RA
36  2016 Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US. ACR20, NNT, PASI75, Ps, PsA
37  2016 Impact of intensive treatment and remission on health-related quality of life in early and established rheumatoid arthritis. cDMARDs, DMARD, HRQoL, PCS, RA, SF-36
38  2016 Infection, malignancy, switching, biosimilars, antibody formation, drug survival and withdrawal, and dose reduction: what have we learned over the last year about tumor necrosis factor inhibitors in rheumatoid arthritis? ---
39  2016 Management of perioperative tumour necrosis factor alpha inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis. ORs, SSIs
40  2016 Predictive factors for achieving low disease activity at 52 weeks after switching from tumor necrosis factor inhibitors to abatacept: results from a multicenter observational cohort study of Japanese patients. ABT, CI, LDA, OR, RA, ROC, TBCR
41  2014 Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews. cDMARDs, CI, DAS28, DMARDs, EQ-5D, HAQ, QALYs, RA, TACIT
42  2014 The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study. ACS, CI, RA
43  2014 The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database. CIs, PY, RA, REAL, REAL, SAEs, SIs
44  2014 Tocilizumab in patients with active rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs or tumor necrosis factor inhibitors: subanalysis of Spanish results of an open-label study close to clinical practice. DMARDs, RA
45  2012 Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. ACR, AEs, DMARDs, IR, PY, RA
46  2011 Brain-penetrating tumor necrosis factor decoy receptor in the mouse. BBB, mAb, TfR, TNFRs
47  2010 Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. ADA, AST, DMARDs, ETN, INF, LFT, MTX, ULN
48  2007 Coccidioidomycosis in rheumatology patients: incidence and potential risk factors. RA